XWELL (NASDAQ:XWEL – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Analyst Ratings
This is a breakdown of current ratings and target prices for XWELL and iSpecimen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XWELL | 1 | 0 | 0 | 0 | 1.00 |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares XWELL and iSpecimen”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XWELL | $33.90 million | 0.21 | -$16.85 million | ($3.37) | -0.37 |
| iSpecimen | $9.29 million | 0.21 | -$12.50 million | ($7.89) | -0.03 |
iSpecimen has lower revenue, but higher earnings than XWELL. XWELL is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares XWELL and iSpecimen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XWELL | -51.85% | -352.37% | -64.88% |
| iSpecimen | -343.86% | -531.78% | -147.74% |
Risk and Volatility
XWELL has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.
Insider and Institutional Ownership
8.7% of XWELL shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 13.9% of XWELL shares are owned by insiders. Comparatively, 12.2% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
XWELL beats iSpecimen on 6 of the 11 factors compared between the two stocks.
About XWELL
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for XWELL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XWELL and related companies with MarketBeat.com's FREE daily email newsletter.
